Adjuvant treatment for renal cell carcinoma: Do we finally have a major breakthrough?

Clinical Advances in Hematology and Oncology

Volumn 14, Issue 11, 2016, Pages 907-914

  Patel, Devin N ^a   Figlin, Robert A ^a   Kim, Hyung L ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Adjuvant; Kidney cancer; Renal cell carcinoma

Indexed keywords

AXITINIB; CABOZANTINIB; EVEROLIMUS; FLUOROURACIL; GIRENTUXIMAB; INTERLEUKIN 2; MEDROXYPROGESTERONE; PAZOPANIB; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ADJUVANT THERAPY; ARTICLE; DIARRHEA; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; FATIGUE; FOOD AND DRUG ADMINISTRATION; GENETIC HETEROGENEITY; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LAPAROSCOPY; LOADING DRUG DOSE; NEPHRECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; ROBOT ASSISTED SURGERY; TUMOR VOLUME; CARCINOMA, RENAL CELL; CLINICAL TRIAL (TOPIC); KIDNEY NEOPLASMS; MULTIMODALITY CANCER THERAPY; NEOADJUVANT THERAPY; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR RECURRENCE;

CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; KIDNEY NEOPLASMS; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84994779262     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016; 66 (1): 7-30.
2. Ravaud A, Motzer RJ, Pandha HS; S-TRAC Investigators. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy [published online October 9, 2016]. N Engl J Med.
3. Kane CJ, Mallin K, Ritchey J, Cooperberg MR, Carroll PR. Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer. 2008; 113 (1): 78-83.
4. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol. 2001; 166 (5): 1611-1623.
5. Sun M, Thuret R, Abdollah F, et al. Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis. Eur Urol. 2011; 59 (1): 135-141.
6. Ljungberg B, Campbell SC, Choi HY, et al. The epidemiology of renal cell carcinoma. Eur Urol. 2011; 60 (4): 615-621.
7. Cairns P. Renal cell carcinoma. Cancer Biomark. 2010; 9 (1-6): 461-473.
8. Colombo JR Jr, Haber GP, Jelovsek JE, Lane B, Novick AC, Gill IS. Seven years after laparoscopic radical nephrectomy: oncologic and renal functional outcomes. Urology. 2008; 71 (6): 1149-1154.
9. Lane BR, Gill IS. 7-year oncological outcomes after laparoscopic and open partial nephrectomy. J Urol. 2010; 183 (2): 473-479.
10. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009; 373 (9669): 1119-1132.
11. Leibovich BC, Blute ML, Cheville JC, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003; 97 (7): 1663-1671.
12. Fahn HJ, Lee YH, Chen MT, Huang JK, Chen KK, Chang LS. The incidence and prognostic significance of humoral hypercalcemia in renal cell carcinoma. J Urol. 1991; 145 (2): 248-250.
13. Patard JJ, Dorey FJ, Cindolo L, et al. Symptoms as well as tumor size provide prognostic information on patients with localized renal tumors. J Urol. 2004; 172 (6 pt 1): 2167-2171.
14. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003; 348 (17): 1625-1638.
15. Bensalah K, Leray E, Fergelot P, et al. Prognostic value of thrombocytosis in renal cell carcinoma. J Urol. 2006; 175 (3 Pt 1): 859-863.
16. Suppiah R, Shaheen PE, Elson P, et al. Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. Cancer. 2006; 107 (8): 1793-1800.
17. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999; 17 (8): 2530-2540.
18. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol. 2002; 168 (6): 2395-2400.
19. Yaycioglu O, Roberts WW, Chan T, Epstein JI, Marshall FF, Kavoussi LR. Prognostic assessment of nonmetastatic renal cell carcinoma: a clinically based model. Urology. 2001; 58 (2): 141-145.
20. Karakiewicz PI, Briganti A, Chun FK, et al. Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol. 2007; 25 (11): 1316-1322.
21. Patard JJ, Kim HL, Lam JS, et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol. 2004; 22 (16): 3316-3322.
22. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013; 499 (7456): 43-49.
23. Rini B, Goddard A, Knezevic D, et al. A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies. Lancet Oncol. 2015; 16 (6): 676-685.
24. Kjaer M, Frederiksen PL, Engelholm SA. Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen Renal Cancer Study Group. Int J Radiat Oncol Biol Phys. 1987; 13 (5): 665-672.
25. Karr JP, Pontes JE, Schneider S, Sandberg AA, Murphy GP. Clinical aspects of steroid hormone receptors in human renal cell carcinoma. J Surg Oncol. 1983; 23 (2): 117-124.
26. Pizzocaro G, Piva L, Di Fronzo G, et al. Adjuvant medroxyprogesterone acetate to radical nephrectomy in renal cancer: 5-year results of a prospective randomized study. J Urol. 1987; 138 (6): 1379-1381.
27. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002; 20 (1): 289-296.
28. Pizzocaro G, Piva L, Colavita M, et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol. 2001; 19 (2): 425-431.
29. Messing EM, Manola J, Wilding G, et al; Eastern Cooperative Oncology Group/Intergroup trial. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/ Intergroup trial. J Clin Oncol. 2003; 21 (7): 1214-1222.
30. Clark JI, Atkins MB, Urba WJ, et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol. 2003; 21 (16): 3133-3140.
31. Passalacqua R, Caminiti C, Buti S, et al; POLAR-01 Trial Investigators. Adjuvant low-dose interleukin-2 (IL-2) plus interferon (IFN-α) in operable renal cell carcinoma (RCC): a phase III, randomized, multicentre trial of the Italian Oncology Group for Clinical Research (GOIRC). J Immunother. 2014; 37 (9): 440-447.
32. Aitchison M, Bray CA, Van Poppel H, et al. Adjuvant 5-flurouracil, alpha-interferon and interleukin-2 versus observation in patients at high risk of recurrence after nephrectomy for renal cell carcinoma: results of a phase III randomised European Organisation for Research and Treatment of Cancer (Genito-Urinary Cancers Group) /National Cancer Research Institute trial. Eur J Cancer. 2014; 50 (1): 70-77.
33. Galligioni E, Quaia M, Merlo A, et al. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guérin: five-year results of a prospective randomized study. Cancer. 1996; 77 (12): 2560-2566.
34. Adler A, Gillon G, Lurie H, et al. Active specific immunotherapy of renal cell carcinoma patients: a prospective randomized study of hormono-immuno-versus hormonotherapy. Preliminary report of immunological and clinical aspects. J Biol Response Mod. 1987; 6 (6): 610-624.
35. Wood C, Srivastava P, Bukowski R, et al; C-100-12 RCC Study Group. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet. 2008; 372 (9633): 145-154.
36. Jocham D, Richter A, Hoffmann L, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet. 2004; 363 (9409): 594-599.
37. Dorai T, Sawczuk IS, Pastorek J, Wiernik PH, Dutcher JP. The role of carbonic anhydrase IX overexpression in kidney cancer. Eur J Cancer. 2005; 41 (18): 2935-2947.
38. Wang Y, Wang XY, Subjeck JR, Kim HL. Carbonic anhydrase IX has chaperone-like functions and is an immunoadjuvant. Mol Cancer Ther. 2008; 7 (12): 3867-3877.
39. Chamie K, Klöpfer P, Bevan P, et al. Carbonic anhydrase-IX score is a novel biomarker that predicts recurrence and survival for high-risk, nonmetastatic renal cell carcinoma: data from the phase III ARISER clinical trial. Urol Oncol. 2015; 33 (5): 204.e25-e33. doi: 10.1016/j.urolonc.2015.02.013.
40. Beroukhim R, Brunet JP, Di Napoli A, et al. Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res. 2009; 69 (11): 4674-4681.
41. Ohh M, Park CW, Ivan M, et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol. 2000; 2 (7): 423-427.
42. Zhong H, Chiles K, Feldser D, et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/ PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 2000; 60 (6): 1541-1545.
43. Keefe SM, Nathanson KL, Rathmell WK. The molecular biology of renal cell carcinoma. Semin Oncol. 2013; 40 (4): 421-428.
44. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004; 64 (19): 7099-7109.
45. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011; 378 (9807): 1931-1939.
46. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010; 28 (6): 1061-1068.
47. Choueiri TK, Escudier B, Powles T, et al; METEOR investigators. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016; 17 (7): 917-927.
48. Hudes G, Carducci M, Tomczak P, et al; Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007; 356 (22): 2271-2281.
49. Motzer R, Hutson T, Glen H, et al. Randomized phase II, three-arm trial of lenvatinib (LEN), everolimus (EVE), and LEN EVE in patients (pts) with metastatic renal cell carcinoma (mRCC) [ASCO abstract 4506]. J Clin Oncol. 2015; 33 (15) (suppl).
50. Escudier B, Pluzanska A, Koralewski P, et al; AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007; 370 (9605): 2103-2111.
51. Haas NB, Manola J, Uzzo RG, et al. Adjuvant sunitinib or sorafenib for highrisk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2016; 387 (10032): 2008-2016.
52. Kim HL, Halabi S, Li P, et al; Alliance for Clinical Trials in Oncology. A molecular model for predicting overall survival in patients with metastatic clear cell renal carcinoma: results from CALGB 90206 (Alliance). EBioMedicine. 2015; 2 (11): 1814-1820.